As an initial adaptive immune system against phages and foreign genetic material in prokaryotes, the CRISPR/Cas9 system is not only widely used for treating various genetic diseases,[41, 42, 43, 44] but also for eradicating various viral infections, including HBV infection.[45, 46, 47, 48] Since RNase P and RNase Z do not require specific sequences to cleave tRNA precursors,[20] gHBV1 and gHBV2 can be efficiently released from the tRNASUAG‐gHBV1‐tRNASUAG‐gHBV2‐tRNASUAG tandem array. Here, ELAC1 is linked to hereditary disease.